New Cancer Cell Therapy Shows Promise in Solid Tumors

Patients with some of the toughest cancers to treat are getting new hope from a cell therapy that solves one of medicine's biggest puzzles: how to fight tumors without burning out the immune system.

Researchers at Penn Medicine just released the first results from a clinical trial testing KIR-CAR, a new type of CAR T cell therapy that targets ovarian cancer, mesothelioma, and bile duct cancer. Unlike traditional CAR T cells that stay constantly activated and eventually wear out, this new design lets cells rest between attacks.

"This is exciting because we're seeing good efficacy signals, even at low doses, and limited toxicity in cancer types that have never had an approved cell therapy," said Dr. Janos Tanyi, who's leading the trial.

The innovation comes down to smart engineering. Traditional CAR T cells work like a light switch stuck in the "on" position, constantly draining energy until they can't fight anymore. The new KIR-CAR design splits the work between two separate chains, one that finds cancer cells and another that triggers the attack. When no tumor is nearby, the cells power down and rest.

All nine patients in this early report had already tried an average of four different treatments before enrolling. These weren't people with easy options left. Four patients saw their disease stabilize, and one patient experienced actual tumor shrinkage that's still continuing.

The safety results matter just as much. Only three patients experienced mild cytokine release syndrome, a manageable side effect. Nobody developed the dangerous brain swelling that sometimes occurs with standard CAR T therapy.

The therapy targets mesothelin, a protein that shows up on several solid tumor cancers but barely appears on healthy cells. That specificity helps explain why patients aren't experiencing severe side effects. For context, about 70 percent of ovarian cancers come back after standard treatment, leaving patients desperate for alternatives.

The Ripple Effect

This trial represents years of work trying to crack the solid tumor problem. CAR T therapy transformed blood cancer treatment, saving lives in leukemia and lymphoma patients who had run out of options. But solid tumors have remained stubbornly difficult.

If KIR-CAR continues performing well as researchers increase the dose, it could open doors for many cancer types. The Penn team is enrolling 42 total patients across four medical centers, with plans to move into Phase II trials once they determine the optimal dose. Blood samples already show that CAR T cells are multiplying more robustly at higher doses, exactly what researchers hoped to see.

The technology came from Verismo Therapeutics, a Penn spinout company, demonstrating how academic research can translate into real treatments. Patients who qualify for the ongoing trial have mesothelin-expressing cancers and have already tried at least one standard treatment.

Nine patients may seem like a small number, but in rare and aggressive cancers, every data point represents someone who needed this option.